{"id":633643,"date":"2026-04-27T07:48:08","date_gmt":"2026-04-27T07:48:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/633643\/"},"modified":"2026-04-27T07:48:08","modified_gmt":"2026-04-27T07:48:08","slug":"already-up-42-this-year-morgans-says-this-asx-healthcare-stock-can-continue-to-rocket","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/633643\/","title":{"rendered":"Already up 42% this year, Morgans says this ASX healthcare stock can continue to rocket"},"content":{"rendered":"\n

ASX healthcare stocks have largely disappointed in 2026.\u00a0 <\/p>\n

The S&P\/ASX 200 Health Care Index (ASX: XHJ) is down more than 22% year to date.\u00a0<\/p>\n

However, one exception has been the outperformance of Tetratherix Ltd (ASX: TTX<\/a>).\u00a0<\/p>\n

\"Health<\/p>\n

Image source: Getty Images<\/p>\n

Company overview <\/p>\n

Tetratherix engages in the development of a biostealth fluid matrix for regenerative medicine.\u00a0<\/p>\n

The firm offers Tetramatrix as its primary product. It develops a biostealth fluid matrix that evolves regenerative medicine through the use of the firm’s Tetramatrix platform technology.\u00a0 <\/p>\n

Its share price has rocketed in 2026, up 42% since the start of the year.\u00a0<\/p>\n

Last week, the company released a quarterly update<\/a>. <\/p>\n

Tetratherix<\/a> reported a strong quarter, highlighting progress toward commercialising its Tegenix product via a global agreement with Henry Schein and expanding into precision medicine with its STEPP drug-delivery platform, including a lucrative R&D deal with Superpower.\u00a0<\/p>\n

The company also advanced multiple clinical programs with positive tissue-healing results and expects FDA clearance for its bone regeneration technology later this year.<\/p>\n

Morgans said the report reinforces that the ASX biotech company continues to tick off key milestones<\/a> towards commercialisation.<\/p>\n

What is Morgans’ latest view on this ASX healthcare stock? <\/p>\n

According to Morgans, this ASX healthcare stock is making solid progress in line with previously stated timelines across each of its franchises.\u00a0<\/p>\n

We remain focused on upcoming catalysts across the four franchisees including: FDA clearance for the bone regeneration product Tegenix and TegenEOS); clinical progress for the tissue spacing products (Tutelix and Optelex) and the tissue healing products (TetraDerm); and product supply in the precision medicine franchise (STEPP).<\/p>\n

Updated price target\u00a0 <\/p>\n

In a recent note out of Morgans, the broker said it has made no changes to its forecasts.\u00a0<\/p>\n

However, it has reduced its price target to $6.84 (previously $7.03).\u00a0<\/p>\n

We maintain our SPECULATIVE BUY recommendation and expect the cadence of news flow to increase over the balance of the year.<\/p>\n

At the time of writing, this ASX healthcare stock is trading for approximately $4.71.\u00a0<\/p>\n

Based on the updated price target from Morgans, this indicates a further upside of approximately 45%.\u00a0<\/p>\n

Foolish Takeaway\u00a0 <\/p>\n

It’s worth noting that investing in biotech stocks can come with big upside, but equal risk.\u00a0<\/p>\n

Many of these types of companies are early-stage or pre-revenue, meaning their valuations often hinge on clinical trial results, regulatory approvals, or breakthrough announcements.\u00a0<\/p>\n

On the flip side, successful outcomes can lead to rapid share price appreciation, making the sector attractive to investors willing to tolerate volatility.<\/p>\n

The key is understanding that this space is driven more by binary outcomes and sentiment than steady earnings, so diversification<\/a> and careful research are essential to managing the risk\/reward balance.<\/p>\n

As Morgans correctly pointed out, FDA clearance and clinical progress will be key factors to monitor for this ASX healthcare stock.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"ASX healthcare stocks have largely disappointed in 2026.\u00a0 The S&P\/ASX 200 Health Care Index (ASX: XHJ) is down…\n","protected":false},"author":2,"featured_media":622895,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-633643","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/633643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=633643"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/633643\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/622895"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=633643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=633643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=633643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}